causal
Rebates Create Floor Not Ceiling on Prices
Because commercial-plan rebates are reported at only 20-30% off a list price that has itself risen ~60% over four years, the post-rebate price still rises year over year and becomes a floor rather than a ceiling, against which new drugs can launch even higher and look cheap, and generics can drop just slightly and claim to be a bargain.
causalpending
Speaker
Robin FeldmanEvidence Quote
“that becomes a floor--you know, not really a ceiling; and new drugs can come out even higher than that and look cheap in comparison.”
Created: 6/13/2026, 12:12:41 AM
Your notes
Loading notes...